Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.43 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25569790 | 0.88 | HPGD (0.47) | HPGDHSD17B3CTNNB1WNT3AMAPT | |
| SCHEMBL25569816 | 0.88 | ATM (0.44) | HPGDCTNNB1WNT3AMAPTALDH1A1 | |
| SCHEMBL12676625 | 0.83 | CTNNB1 (0.40) | CTNNB1WNT3AMAPTALDH1A1NPC1 | |
| SCHEMBL25569462 | 0.81 | CTNNB1 (0.35) | HPGDCTNNB1WNT3AMAPTALDH1A1 | |
| SCHEMBL10691604 | 0.79 | HPGD (0.44) | HPGDHSD17B3CTNNB1WNT3AMAPT | |
| SCHEMBL7085094 | 0.78 | HSD17B3 (0.49) | HSD17B3STS | |
| SCHEMBL3348087 | 0.76 | KDM1A (0.43) | HSD17B3MAPTALDH1A1GAAKDM4E | |
| SCHEMBL25569825 | 0.75 | MAPT (0.35) | CTNNB1WNT3AMAPTALDH1A1NPC1 | |
| SCHEMBL10687927 | 0.75 | ATM (0.44) | HPGDCTNNB1WNT3AMAPTALDH1A1 | |
| SCHEMBL24197468 | 0.73 | MAPT (0.34) | HPGDMAPTALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | HPGD 1883/4885HSD17B3 406/4885CTNNB1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.